Viking Therapeutics: Investors Meeting Reality Of The Obesity Market
Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Evercore ISI Sticks to Their Hold Rating for Eli Lilly & Co (LLY)
Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares closed ...
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
kalkinemedia1d
Eli Lilly (NYSE:LLY) Faces Drop – What's Ahead for the Pharma Giant?
Headlines,Eli Lilly Shares Experience a Decline,Key Analyst Activity and Ratings for LLY,What's Next for Eli Lilly's ...
Taking Ozempic for weight loss? You might find other benefits, too - and a few risks
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.
Health Care Up on GLP-1 Alzheimer's Data — Health Care Roundup
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
The Pharma Letter2d
Study shows benefits and risks from GLP-1RAs
A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), ...
Should You Buy the Dip in Eli Lilly Stock Right Now?
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...